Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Google Secures Pentagon AI Deal for Classified Projects 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
STAMFORD, Conn., May 02, 2017 -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, will announce financial results for the first quarter ended March 31, 2017 on May 9, 2017 before the NASDAQ market open.
The company will not be conducting a conference call in conjunction with this earnings release.
About Loxo Oncology
Loxo Oncology is a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers. Our pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. We believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, thereby delivering best-in-class disease control and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company's website at www.loxooncology.com.
Contacts for Loxo Oncology, Inc.
Company:
Jacob S. Van Naarden
Chief Business Officer
[email protected]
Investors:
Peter Rahmer
The Trout Group, LLC
646-378-2973
[email protected]
Media:
Dan Budwick
1AB Media
973-271-6085
[email protected]
